Magnetic resonance imaging (MRI) relies on the relaxation properties of excited hydrogen nuclei in water and in lipids to create images. When a target object to be imaged is placed in a uniform magnetic field, the forces in the magnetic field cause the spins of atomic nuclei having a non-zero spin to align in a particular manner with the applied magnetic field. By way of example, hydrogen atoms have a simple spin (1/2) and therefore align either parallel or antis-parallel (parallel but oppositely directed or oriented) to the magnetic field. A radio frequency pulse (RF) is then applied in a direction perpendicular to the magnetic field and removed. When the RF signal is removed, the atomic nuclei relax. During the relaxation process, the nuclei release energy by emitting an RF signal unique to the nuclei, which may be measured by a conductive field coil placed around the target object. This measurement is processed or reconstructed to obtain the magnetic resonance images.
The signal intensity of a given tissue type depends upon the density of the protons in the tissue. However, the contrast of the image, or the difference in luminance or color that distinguishes one object from another in the same field of view also depends on two other tissue-specific parameters: the longitudinal relaxation time (T1) and the transverse relaxation time (T2). T1 defines the time required for the displaced nuclei to return to equilibrium, that is to say, the time required for the nuclei to realign themselves in the magnetic field. T2 is the time required for the signal emitted by a specific tissue type to decay, or stated differently, T2 is the time constant for the decay of transverse magnetization arising from natural atomic and molecular interactions within the target object. However, in practice, the observed decay rate of transverse magnetization is faster than the mathematically predicted decay rate as a result of inhomogeneities in the magnetic field caused by magnet defects or magnetic field distortions. The observed decay rate is represented by T2* and is always shorter than T2.
Image contrast is the difference in luminance or color that distinguishes one object from another in the same image. Contrast is created by using a selection of image acquisition parameters that weighs signals by T1, T2 or T2*, or no relaxation time. These images are known in the art as proton density images. For example, in the brain, T1-weighting (T1w) causes the nerve connections of white matter to appear white, and the congregations of neurons of gray matter to appear gray. Cerebrospinal fluid appears dark.
Contrast agents may be used to enhance tissue contrast in MRI images by inducing magnetic susceptibility contrast effects when injected. Magnetic susceptibility is a property of materials and is measure of the degree to which a material will become magnetized in an applied magnetic field. Materials may be classified into two groups based upon their individual susceptibility—paramagnetic materials and diamagnetic materials. Paramagnetic materials align with an applied magnetic field and are attracted to it. Diamagnetic materials on the other hand align against an applied magnetic field and are repelled by it. Accordingly, most commonly a paramagnetic contrast agent, typically a gadolinium compound, is employed to enhance MRI image contrast. As will be discussed in greater detail below, several different contrast enhancing agents may also be used.
Gadolinium-enhanced tissues and fluids appear extremely bright in weighted images, thereby providing high contrast sensitivity which facilitates the detection of vascular issues (tumors) and permits assessment of brain perfusion, such as that which occurs following a stroke. Cerebral blood volume (CBV) and cerebral blood flow (CBF) can also be measured, and other hemodynamic and vascular parameters can be derived from these measurements. However, a significant problem associated with the use of gadolinium-based contrast agents is their migration or leakage from a patient's blood vessels, This leakage results in undesirable T1 and T2 relaxation effects that significantly complicate the ability of treating physicians to evaluate T1-weighted images.
Image-based techniques have been developed to determine the effects of brain tumors and to address the problem of proper assessment of patients suffering from brain abnormalities. These techniques are integral to the management of patients with brain tumors and other neuro abnormalities and critical for the evaluation of new treatments in clinical trials. The standard approach requires a visual assessment of the contrast-agent enhancement (T1w+contrast agent) of a region of interest (ROI) in a magnetic resonance image (MRI). As shown in
Moreover, the development of automated methods to determine regions of interest on T1+C ROI images has several limitations. Unlike x-ray angiography (XA) or computed tomography (CT), the pixel values for the same tissue type on MR images vary widely due to a number of factors, even for the same sequence type. Some non-contrast enhancing tissues, such as blood products, can also appear bright, thus further confounding interpretation. Visual comparison of pre- and post-contrast images or subtraction of a pre-contrast image from the post-contrast image can compensate for these limitations, inasmuch as the process highlights areas of contrast enhancement. Nonetheless, as illustrated in
Prior art attempts to address the above-referenced problems include the following published works:
The first Nyu'l paper showing standardized mapping of image intensities (no difference map generation, no application of the Difference color look up table [CLUT]):
Nyu'l L. G., Udupa J. K., Zhang, X. New variants of a method of MRI scale standardization. IEEE Trans Med Imaging 2000; 19:143-50 Cross Ref Medline.
The first report of the approach to standardize and subtract:
Jensen T. R., Schmainda, K. M. Computer-aided detection of brain tumor invasion using must parametric MRI. Magn Reson Imaging 2009; 30:481-89.
The first initial disclosure on the Delta T1 mapping process (using standardization, subtraction, Difference CLUT) was in 2010 (ISMRM):
Bedekar, D, Jensen, T., Rand, S., et al., Delta T1 method: an automatic post-contrast ROI selection technique for brain tumors. In: Proceedings of the Annual Meeting of the international Society for Magnetic Resonance in Medicine, Stockholm, Sweden May 1-7, 2010.
A method that uses a Gaussian normalization approach to pre-process the pre- end post-contrast T1-weighted images before subtraction; the Difference CLUT is not used:
Ellingson, B. M., Kim, H. J., Woodworth, D. C., et al., Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology 2014; 271:200-10.
An application of the dT1 to clinical trial data, showing it can provide equivalent and/or superior results compared to the current method of using central expert feeders;
Schmainda, K. M., Prah M. A., Zhang, Z., Snyder, B. S., Rand, S. D., Jensen, T. R. Barboriak, D. P., Boxerman, J. L., Quantitative delta T1 (dT1) as a replacement for adjudicated central reader analysis of contrast-enhancing tumor burden: A sub analysis of the American College of Radiology imaging Network 6677/Radiation Therapy Oncology Group 0625 Multicenter Brain Tumor Trial. AMR Am. J. Neuroradiol. 2019 40(7):1132-1139.
While simple “difference” maps are known in the art, they are known to be of relative (not quantitative) in value, do not account for confounding factors (such as post-surgical blood products), and are not able to identify subtle regions of true enhancement. Other prior art methods do not produce resulting maps on a consistent quantitative scale, cannot be generated automatically, do not routinely use the red/blue FLOW-CLUT, and have not demonstrated the ability to predict response to tumor recurrence such as illustrated in
In view of the foregoing, it is apparent to those skilled in the art that a need exists for a system and a method for generating delta T1 maps that may be used to quantify levels of contrast enhancement by subtracting pre- from post-contrast T1-weighted images, each of which were first transformed to a quantitative scale.
A system and a method for generating and displaying quantitative delta T1-weighted images or maps which are displayed using a “FLOW” (red/blue) color look up table (CLUT).
In an embodiment, the output is a quantitative difference (delta T1 or dT1) map that makes possible the objective identification (i.e., automation) of a region of interest across time and patients. The delta T1 maps have the further benefits of eliminating factors (such as post-surgical or treatment-related blood products) that can confound the current practice of subjectively evaluating T1-weighted images and can manifest subtle regions of true enhancement not otherwise visible.
In another embodiment, a method is disclosed for generating delta T1-weighted maps automatically without any additional processing steps or manual intervention.
In yet another embodiment, a method is provided which employs empirically determined cutoff thresholds that delineate enhancing and non-enhancing regions in the delta T1-weighted images.
In still another embodiment a method is disclosed for generating delta T1-weighted maps which employs a commonly available FLOW-CLUT (red-blue) to provide rapid and objective visualization via red image enhancement.
In another embodiment, a method is disclosed for generating delta T1-weighted maps automatically which computationally retains small values of “blue” (non-enhancing) regions that provide the user with easy spatial visualization of underlying anatomy.
In yet another embodiment, a method is disclosed for generating delta T1-weighted maps automatically that are repeatable and consistent over time.
Other advantages of the present invention will be readily apparent to one skilled in the art from the description, the figures, and the appended claim.
For a more complete understanding of the present disclosure and its advantages, reference is now made to the following description taken in conjunction with the accompanying drawings. The patent application file contains at least one drawing executed in color. Copies of this patent or patent application with color drawing(s) will be provided by the Office upon request and payment of the necessary
The method of generating and displaying quantitative T1-weighted subtraction maps, also referred to herein as delta T1 maps, includes the following steps:
1. Pre- and post-contrast T1-weighted images 10 and 15 respectively as shown in
2. Both images are co-registered to each other to a consistent quantitative scale using commonly available image co-registration algorithms incorporating a fixed set of pre- and post-contrast images on a voxel by voxel basis as illustrated at 20 and 25 in
3. Pre- and post-contrast T1-weighted images are then standardized or calibrated as shown in
4. At step 4, illustrated in
5. An empirically determined threshold (3000 or higher on the standardized scale) is applied to each of the one or more delta T1 maps to obtain an enhancing lesion region of interest (ROI) illustrated at 40 in the dT1image 45 in
6. Noisy voxels mainly around skull and eyes area can be manually removed.
7. As shown in
Imperfections in the image acquisition process can result in image intensity variations such that the same tissue in different locations have different image intensities. These image artifacts are referred to as bias field, shading, intensity inhomogeneity, or intensity nonuniformity. Although the bias field is often difficult to observe by the human eye, it can degrade the accuracy of automated analysis techniques significantly. Accordingly, a number of techniques or methods have been proposed to correct the bias field in medical images, and the method of creating dT1 maps in accordance with the instant invention optionally, intermediate step 1 and step 2, includes a bias correcting step that may be performed using a commonly available algorithm (e.g., N4ITK). However, this step may be omitted without departing from he scope of the present invention.
The process defined in the above steps can be automated in repeatable and consistent image processing algorithm, requiring a few seconds (<10 seconds) of processing time.
The novel methodology herein disclosed is a software application that can be integrated into MRI imaging platforms as a pre-processing step for neuro assessment. The process steps may be stored on a non-transitory computer-readable storage medium or hardware such as a disc, a removable hard drive, or a thumb drive and the like adapted to store non-transitory process instructions that, when executed by a computer, cause it to perform the process steps herein disclosed. The application identifies the pre- and post-contrast T1 weighted images automatically, performs the above processing steps, and automatically generates a map that can be used within any DICOM (Digital Information and Communication in Medicine) medical imaging platform.
Changes may be made in the above methods and systems without departing from the scope hereof. It should be noted that the matter contained in the above description and/or shown in the accompanying figures should be interpreted as illustrative and not in a limiting sense. The following claims are intended to cover all generic and specific features described herein, as well as all statements of the scope of the present systems.
This application claims priority to U.S. Provisional Patent Application No. 63/088,295, filed on Oct. 6, 2020, the entire disclosure of which is incorporated herein by reference.
Number | Date | Country | |
---|---|---|---|
63088295 | Oct 2020 | US |